Cyclooxygenase 2 Inhibitors

• 

  Subject Areas on Research

  • 3,4-Diaryl-5-hydroxyfuranones: highly selective inhibitors of cyclooxygenase-2 with aqueous solubility. 
  • A new prostate cancer therapeutic approach: combination of androgen ablation with COX-2 inhibitor. 
  • A new structural variation on the methanesulfonylphenyl class of selective cyclooxygenase-2 inhibitors. 
  • A selective inhibitor of cyclooxygenase-2 reverses endotoxin-induced pyretic responses in non-human primates. 
  • Acute urinary retention associated with the use of cyclooxygenase-2 inhibitors. 
  • Aspirin and COX-2 inhibitor use in patients with stage III colon cancer. 
  • Balancing the cyclooxygenase portfolio. 
  • Biochemical and pharmacological profile of a tetrasubstituted furanone as a highly selective COX-2 inhibitor. 
  • Biphasic effects of interleukin-1beta on osteoblast differentiation in vitro. 
  • COX-2-derived prostacyclin modulates vascular remodeling. 
  • Celecoxib With Neoadjuvant Chemotherapy for Breast Cancer Might Worsen Outcomes Differentially by COX-2 Expression and ER Status: Exploratory Analysis of the REMAGUS02 Trial. 
  • Cell cycle effects of nonsteroidal anti-inflammatory drugs and enhanced growth inhibition in combination with gemcitabine in pancreatic carcinoma cells. 
  • Central nervous system concentrations of cyclooxygenase-2 inhibitors in humans. 
  • Compensatory hypertrophy induced by ventricular cardiomyocyte-specific COX-2 expression in mice. 
  • Controlled release of etoricoxib from poly(ester urea) films for post-operative pain management. 
  • Cyclooxygenase-1 and -2 knockout mice demonstrate increased cardiac ischemia/reperfusion injury but are protected by acute preconditioning. 
  • Cyclooxygenase-two (COX-2) modulates proliferation in aggressive fibromatosis (desmoid tumor). 
  • Development and longitudinal validation of the overall benefit of analgesia score: a simple multi-dimensional quality assessment instrument. 
  • Differential regulation of renin and Cox-2 expression in the renal cortex of C57Bl/6 mice. 
  • E-prostanoid-3 receptors mediate the proinflammatory actions of prostaglandin E2 in acute cutaneous inflammation. 
  • Effect of Celecoxib vs Placebo Added to Standard Adjuvant Therapy on Disease-Free Survival Among Patients With Stage III Colon Cancer: The CALGB/SWOG 80702 (Alliance) Randomized Clinical Trial. 
  • Effects of aggregation of drug and diagnostic codes on the performance of the high-dimensional propensity score algorithm: an empirical example. 
  • Eicosanoid modulation in advanced lung cancer: cyclooxygenase-2 expression is a positive predictive factor for celecoxib + chemotherapy--Cancer and Leukemia Group B Trial 30203. 
  • Enantiomeric metabolic interactions and stereoselective human methadone metabolism. 
  • Evidence for a pro-proliferative feedback loop in prostate cancer: the role of Epac1 and COX-2-dependent pathways. 
  • Host response to infection: the role of CpG DNA in induction of cyclooxygenase 2 and nitric oxide synthase 2 in murine macrophages. 
  • How direct-to-consumer television advertising for osteoarthritis drugs affects physicians' prescribing behavior. 
  • Hurry up and slow down: lessons in drug development from the COX-2 inhibitors. 
  • Impact of FDA Actions, DTCA, and Public Information on the Market for Pain Medication. 
  • In vitro metabolism of the COX-2 inhibitor DFU, including a novel glutathione adduct rearomatization. 
  • Inhibition of haematogenous metastasis of colon cancer in mice by a selective COX-2 inhibitor, JTE-522. 
  • Inhibitors of prostaglandin synthesis inhibit human prostate tumor cell invasiveness and reduce the release of matrix metalloproteinases. 
  • Lack of correlation between the central anti-nociceptive and peripheral anti-inflammatory effects of selective COX-2 inhibitor parecoxib. 
  • Mathematical modeling of the Phoenix Rising pathway. 
  • Matrix-based Molecular Descriptors for Prospective Virtual Compound Screening. 
  • Modeling adult COX-2 cerebrospinal fluid pharmacokinetics to inform pediatric investigation. 
  • Molecular staging and the selection of therapy for non-small cell lung cancer. 
  • Nonsteroidal antiinflammatory drug use among patients with GI bleeding. 
  • Perioperative COX-2 inhibitors: knowledge and challenges. 
  • Perspectives in colorectal cancer - Sixth Annual Conference. Metastatic colorectal cancer. 
  • Phase III Randomized, Placebo-Controlled, Double-Blind Trial of Celecoxib in Addition to Standard Chemotherapy for Advanced Non-Small-Cell Lung Cancer With Cyclooxygenase-2 Overexpression: CALGB 30801 (Alliance). 
  • Prostaglandin-mediated effects in early canine corpus luteum: In vivo effects on vascular and immune factors. 
  • Punicalagin inhibits neuroinflammation in LPS-activated rat primary microglia. 
  • Pyridazinones as selective cyclooxygenase-2 inhibitors. 
  • Quantifying intrinsic specificity: a potential complement to affinity in drug screening. 
  • ROC curve estimation under test-result-dependent sampling. 
  • Resistance to hypertension mediated by intercalated cells of the collecting duct. 
  • Rofecoxib [Vioxx, MK-0966; 4-(4'-methylsulfonylphenyl)-3-phenyl-2-(5H)-furanone]: a potent and orally active cyclooxygenase-2 inhibitor. Pharmacological and biochemical profiles. 
  • Role of prostacyclin in the cardiovascular response to thromboxane A2. 
  • Skin tight: macrophage-specific COX-2 induction links salt handling in kidney and skin. 
  • Synthesis and biological evaluation of 3-heteroaryloxy-4-phenyl-2(5H)-furanones as selective COX-2 inhibitors. 
  • Synthesis, characterization, and activity of metabolites derived from the cyclooxygenase-2 inhibitor rofecoxib (MK-0966, Vioxx). 
  • Testosterone in prostate cancer: the Bethesda consensus. 
  • The discovery of rofecoxib, [MK 966, Vioxx, 4-(4'-methylsulfonylphenyl)-3-phenyl-2(5H)-furanone], an orally active cyclooxygenase-2-inhibitor. 
  • The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. 
  • The effects of physician specialty and patient comorbidities on the use and discontinuation of coxibs. 
  • The role of COX-2 in heart pathology. 
  • Use of nonsteroidal antiinflammatory drugs and distal large bowel cancer in whites and African Americans.